Phase I Study of Decitabine-Mediated Gene

Oct 1, 2006 - NY-ESO-1, MAGE-3, and p16 expression in tumor biopsies. Long oligonucleotide arrays .... Two cycles constituted one course of therapy. B...

0 downloads 0 Views 394KB Size

Recommend Documents

Oct 13, 2006 - the adaptation and evaluation of the SFP10–14 ... Twenty-one percent of pupils ... 15–19 years are 16 times more likely to die than those of a ...

chemistry in 10 of 12 patients and integrated viral sequences by PCR in 3 of 6 ...... effects, following gene-directed enzyme prodrug therapy, has previously only ...

laire, Département de Biologie Clinique, Institut Gustave Roussy, 39 rue Camille ...... Dr. M. Perricaudet, Dr. K. Benhioud, Dr. H. Haddada, Dr. C. Tan- crede, Dr.

liters/h/m2 (n = 6; P < 0.002), denoting a departure from linear pharma- cokinetic behavior. The rather low steady ... ~To whom requests for reprints should be addressed, at the Laboratory of Pharma ceutical Chemistry, National ...... As anticipated

would experience grade 3 or 4 toxicity, and thus to define a dose suitable for broad phase II evaluation. ...... (D-19466; lobaplatin) admin istered daily for 5 days.

May 15, 2008 - hamster, and human cells to rBBX-01 (EC50 assay .... avastin; Gem/Dox, generic gemcitabine + pegylated liposomal doxorubicin; HKI-272, ...

Departments of Medicine [J. L, A. T. H.. W. D. B., C. J.. .... abbreviations used are: ..... ftn. QJ . ÖU. uÜ 60 i. 40. 5 et. 20 • "' •IO •121. 16)- •141. 131.

May 15, 2009 - Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour ... Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy ...

long-term venous access catheters has made prolonged infusion of vinblastine and ... 3The abbreviations used are: CVI, continuous vinblastine infusion; VLB«, steady-state serum ..... N. Engl. J. Med., 291: 127-133, 1974. 18. Ratain, M. J. ...

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile of paclitaxel (20).

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

Oct 15, 2008 - Doxorubicin and trabectedin pharmacokinetics were not altered .... hematologic drug-related effects, and creatinine phosphokinase eleva-.

Jul 15, 1995 - Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse. Antibody ... V. V., D. B., H. W., G. H.¡,Laboratory Medicine ¡H.F.], and Clinical Immunology and Biological Therapy [J. L M.],. The University of ....

[CANCER RESEARCH 62, 4968–4976, September 1, 2002]. Phase I .... The costs of publication of this article were defrayed in part by the payment of page ... contained most of the cancer. Injection of the Ad5-CD/TKrep adenovirus was performed on an ou

Nov 28, 2014 - Supplemental digital content is available for this article. Direct URL citations .... than 7 days, or grade 4 thrombocytopenia. Any life- threatening .... Other (Filipino). 7.7. 0. 5.3. Sex (%). Male. 61.5. 50.0. 57.9. Age (years). Mea

treatment of multiple myeloma, ovarian cancer, breast cancer, and neuroblastoma (3–5). .... ferases, -glutamyl-aminotransferase, alkaline phosphatase, and.

were no DLTs in the six patients evaluated at the first two dose levels of 600 and 900 g/m2. Reversible grade 4 transaminitis occurred in two of nine patients after ...

to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer. Res.

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

Apr 20, 2010 - Blood sampling for PK and drug-drug interaction studies was done. ... trabectedin every 2 weeks in patients with advanced solid tumors. J Clin.

Phase I Study of Topoisomerase I Inhibitor Exatecan Mesylate. (DX-8951f) Given as Weekly 24-Hour Infusions Three of. Every Four Weeks. Sunil Sharma,1 ...

infusion solutions are compatible with PVC i.v. infusion bags and are chemically stable ... two cycles of treatment. Disease assessments by any tech- ...... Click on "Request Permissions" which will take you to the Copyright Clearance Center's.